다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Drug design, development and therapy, v.8, 2014년, pp.279 - 284
Zhang, Dongshan (Departments of Emergency Medicine and Nephrology, Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China) , Yang, Ruhao (Departments of Emergency Medicine and Nephrology, Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China) , Wang, Shixuan (Department of Cellular Biology and Anatomy, Medical College of Georgia, Georgia Regents University and Charlie Norwood VA Medical Center, Augusta, GA, USA) , Dong, Zheng (Departments of Emergency Medicine and Nephrology, Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China)
AI-Helper
Paclitaxel (Taxol), one of the most important anticancer drugs, has been used for therapy of different types of cancers. Mechanistically, paclitaxel arrests cell cycle and induces cell death by stabilizing microtubules and interfering with microtubule disassembly in cell division. Recently, it has b...
1 Goldspiel BR Clinical overview of the taxanes Pharmacotherapy 1997 17 110S 125S 9322878
2 Ledwitch K Ogburn R Cox J Taxol: efficacy against oral squamous cell carcinoma Mini Rev Med Chem 2013 13 509 521 23373651
3 Rowinsky EK The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents Annu Rev Med 1997 48 353 374 9046968
4 Mekhail TM Markman M Paclitaxel in cancer therapy Expert Opin Pharmacother 2002 3 6 755 766 12036415
5 Zhou J Zhong DW Wang QW Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-β/Smad activity World J Gasteroenterol 2010 16 26 3330 3334
6 Liu X Zhu S Wang T Paclitaxel modulates TGF-β signaling in scleroderma skin grafts in immunodeficient mice PLoS Med 2005 2 12 e354 16250671
7 Zhang D Sun L Xian W Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-β/Smad activity Lab Invest 2010 90 3 436 447 20142807
8 Sun L Zhang D Fuyou Liu Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192 J Pathol 2011 225 3 364 377 21984124
9 Mirzapoiazova T Kolosova IA Moreno L Sammani S Garcia JG Verin AD Suppression of endotoxin-induced inflammation by paclitaxel Eur Respir J 2007 30 3 429 435 17537765
10 Hellal F Hurtado A Ruschel J Microtubule stabilization reduces scarring and causes axon regeneration after spinal cord injury Science 2011 331 6019 928 931 21273450
11 Tepe G Zeller T Albrecht T Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg N Engl J Med 2008 358 7 689 699 18272892
12 Stone GW Ellis SG Cox DA A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 2004 350 3 221 231 14724301
13 Bharadwaj R Yu H The spindle checkpoint, aneuploidy, and cancer Oncogene 2004 23 11 2016 2027 15021889
14 Brito DA Yang Z Rieder CL Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied The Journal of Cell Biology 2008 182 4 623 629 18710927
15 Jordan MA Wilson L Microtubules as a target for anticancer drugs Nat Rev Cancer 2004 4 4 253 265 15057285
16 Ganguly A Yang H Cabral F Paclitaxel-dependent cell lines reveal a novel drug activity Mol Cancer Ther 2010 9 11 2914 2923 20978163
17 Löwe J Li H Downing KH Refined structure of alpha beta-tubulin at 3.5 A resolution J Mol Biol 2001 313 5 1045 1057 11700061
18 Panis C Lemos LG Victorino VJ Immunological effects of taxol and adryamicin in breast cancer patients Cancer Immunol Immunother 2012 61 4 481 488 21959683
19 Alexandre J Hu Y Lu W Pelicano H Huang P Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species Cancer Res 2007 67 8 3512 3517 17440056
20 Hadzic T Aykin-Burns N Zhu Y Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress Free Radic Biol Med 2010 48 8 1024 1033 20083194
21 Sevko A Michels T Vrohlings M Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model J Immunol 2013 190 5 2464 2471 23359505
22 Sevko A Kremer V Falk C Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice J Immunotoxicol 2012 9 3 275 281 22449053
23 Gan L Chen S Wang Y Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer Cancer Res 2009 69 21 8386 8394 19826044
24 Derynck R Zhang YE Smad-dependent and Smad-independent pathways in TGF-beta family signalling Nature 2003 425 6958 577 584 14534577
25 Dong C Li Z Alvarez R Microtubule binding to Smads may regulate TGF beta activity Mol Cell 2000 5 1 27 34 10678166
26 Brahn E Tang C Banquerigo ML Regression of collagen-induced arthritis with Taxol, a microtubule stabilizer Arthritis Rheum 1994 37 6 839 845 7911665
27 Karbalay-Doust S Noorafshan A Pourshahid SM Taxol and taurine protect the renal tissue of rats after unilateral ureteral obstruction: a stereological survey Korean J Urol 2012 53 5 360 367 22670197
28 Wang C Song X Li Y Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-β1/Smad3 pathway via miR-140 upregulation PLoS One 2013 8 8 e70725 23967091
29 Tsukada T Fushida S Harada S Low-dose paclitaxel modulates tumour fibrosis in gastric cancer Int J Oncol 2013 42 4 1167 1174 23443842
30 Kupfer I Balguerie X Courville P Scleroderma-like cutaneous lesions induced by paclitaxel: a case study J Am Acad Dermatol 2003 48 2 279 281 12582404
31 Eisenbeilss C Weizel J Wolff H Scleroderma-like skin changes following administration of paclitaxel for the treatment of ovarian carcinoma J Dtsch Dermatol Ges 2003 1 6 468 470 16295141
32 Ostoros G Pretz A Fillinger J Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature Int J Gynecol Cancer 2006 16 1 391 393 16515630
33 Sako T Burioka N Watanabe M A case of stage IV advanced lung adenocarcinoma treated effectively using paclitaxel with the fibrosing radiographically on the chest CT Gan To Kagaku Ryoho 2001 28 7 989 992 Japanese 11478149
34 Petrache I Birukova A Ramirez SI Garcia JG Verin AD The role of the microtubules in tumor necrosis factor-ainduced endothelial cell permeability Am J Respir Cell Mol Biol 2003 28 5 574 581 12707013
35 Birukova AA Smurova K Birukov KG Microtubule disassembly induces cytoskeletal remodeling and lung vascular barrier dysfunction: role of Rho-dependent mechanisms J Cell Physiol 2004 201 1 55 70 15281089
36 Kielbassa K Schmitz C Gerke V Disruption of endothelial microfilaments selectively reduces the transendothelial migration of monocytes Exp Cell Res 1998 243 1 129 141 9716457
37 Roberts RL Nath J Friedman MM Gallin JI Effects of taxol on human neutrophils J Immunol 1982 129 5 2134 2141 6126502
38 Lee M Jeon YJ Paclitaxel-Induced Immune Suppression is sociated with NF-κB Activation Via Conventional PKC Isotypes in Lipopolysaccharide-Stimulated 70Z/3 Pre-B Lymphocyte Tumor Cells Mol Pharmacol 2001 59 2 248 253 11160860
39 Byrd CA Bornmann W Erdjument-Bromage H Heat shock protein 90 mediates macrophage activation by Paclitaxel and bacterial lipopolysaccharide Proc Natl Acad Sci U S A 1999 96 10 5645 5650 10318938
40 Lee M Yea SS Jeon YJ Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation Int J Immunopharmacol 2000 22 8 615 621 10988356
41 Shimazu R Akashi S Ogata H MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4 J Exp Med 1999 189 11 1777 1782 10359581
42 Zimmer SM Liu J Clayton JL Paclitaxel binding to human and murine MD-2 J Biol Chem 2008 283 41 27916 27926 18650420
43 Resman N Gradisar H Vasl J Taxanes inhibit human TLR4 signaling by binding to MD-2 FEBS Lett 2008 582 28 3929 3934 18977229
44 Zhang D Li Y Liu Y Paclitaxel ameliorates lipopolysaccharide-induced kidney injury by binding myeloid differentiation protein-2 to block Toll-like receptor 4-mediated nuclear factor-κB activation and cytokine production J Pharmacol Exp Ther 2013 345 1 69 75 23318472
45 Sengottuvel V Leibinger M Pfreimer M Andreadaki A Fischer D Taxol Facilitates Axon Regeneration in the Mature CNS J Neurosci 2011 31 7 2688 2699 21325537
46 Werk M Langner S Reinkensmeier B Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial Circulation 2008 118 13 1358 1365 18779447
47 Siablis D Karnabatidis D Katsanos K Diamantopoulos A Christeas N Kaqadis GC Infrapopliteal application of paclitaxel-eluting stents for critical limb ischemia: midterm angiographic and clinical results J Vasc Interv Radiol 2007 18 11 1351 1361 18003984
48 Schmidt A Piorkowski M Werner M First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome J Am Coll Cardiol 2011 58 11 1105 1109 21884945
49 Cafasso D Schneider P How paclitaxel can improve results in diabetics J Cardiovasc Surg (Torino) 2012 53 1 13 21
50 Indolfi C Coppola C Torella D Arcucci O Chiariello M Gene therapy for restenosis after balloon angioplasty and stenting Cardiol Rev 1999 7 6 324 331 11208244
51 Tepe Gunnar Scheller Bruno Speck Ulrich Paclitaxel-coated angioplasty catheters for local drug delivery Diagn Interv Radiol 2007 13 2 61 63 17562508
52 Park SJ Shim WH Ho DS A paclitaxel-eluting stent for the prevention of coronary restenosis N Engl J Med 2003 348 16 1537 1545 12700373
53 Gershlick A De Scheerder I Chevalier B Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial Circulation 2004 109 4 487 493 14744971
54 Milewski K Afari ME Tellez A Evaluation of efficacy and dose response of different paclitaxel-coated balloon formulations in a novel swine model of iliofemoral in-stent restenosis JACC Cardiovasc Interv 2012 5 10 1081 1088 23078739
55 Byrne RA Neumann FJ Mehilli J Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial Lancet 2013 381 9865 461 467 23206837
56 Sonoda S Honda Y Kataoka T Bonneau HN Taxol-based eluting stents from theory to human validation: clinical and intravascular ultrasound observations J Invasive Cardiol 2003 15 3 109 114 12612382
57 Pires NMM Eefting D de Vries MR Quax PHA Jukema JW Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries Heart 2007 93 8 922 927 17449502
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.